As Gaucher disease is an autosomal recessive disorder, most patients are either homozygotes or compound heterozygotes for glucocerebrosidase mutations. We have encountered a patient with three mutations, two c.1226A→G (1226G, N370S) and one c.1448 T→C (1448C, L444P). This was shown to be due to a gene conversion event in which the sequence of the glucocerebrosidase pseudogene that includes the 1448C mutation had been imposed on a glucocerebrosidase gene that already had the 1226G mutation. The patient had relatively mild disease which had been discovered after an attack of infectious mononucleosis, a relationship that has been observed previously. If it had not been recognized that this patient had the 1226G/1226G,1448C genotype, prenatal testing might have falsely identified a 1226G,1448C/wt (wild type) fetus as having Gaucher disease.

Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, West C, Gelbart T: Gaucher disease: Gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993;52:85–88.
Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1–3.
Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E: A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis and diagnosis of this disorder. J Clin Invest 1990;85:219–222.
Demina A, Boas E, Beutler E: Structure and linkage relationships of the region containing the human L-type pyruvate kinase (PKLR) and glucocerebrosidase (GBA) genes. Hematopathol Mol Hematol 1998;11:63–71.
Beutler E, Gelbart W, Wilder S, Reiner O, Horowitz Z, Horowitz M: The glucocerebrosidase gene and pseudogene. Am J Hum Genet 1988;43:A177.
Sinclair G, Choy FYM, Humphries L: A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Blood Cells Mol Dis 1998;24:420–427.
Zimran A, Horowitz M, Rec TL: A complex allele of the glucocerebrosidase gene associated with a mild clinical course of Gaucher disease. Am J Med Genet 1994;50:74–78.
Eyal N, Wilder S, Horowitz M: Prevalent and rare mutations among Gaucher patients. Gene 1990;96:277–283.
Latham T, Grabowski GA, Theophilus BDM, Smith FI: Complex alleles of the acid β-glucosidase gene in Gaucher disease. Am J Hum Genet 1990;47:79–86.
Beutler E, Gelbart T: Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 1998;24:2–8.
Zimran A, Gelbart T, Beutler E: Linkage of the Pvu II polymorphism with the common Jewish mutation for Gaucher disease. Am J Hum Genet 1990;46:902–905.
Baltimore D: Gene conversion: Some implications for immunoglobulin genes. Cell 1981;24:592–594.
Gorlach A, Lee PL, Roesler J, Hopkins PJ, Christensen B, Green ED, Chanock SJ, Curnutte JT: A p47-phox pseudogene carries the most common mutation causing p47-phox-deficient chronic granulomatous disease. J Clin Invest 1997;100:1907–1918.
White PC, Tusie-Luna MT, New MI, Speiser PW: Mutations in steroid 21-hydroxylase (CYP21). Hum Mutat 1994;3:373–378.
Beutler E: Gaucher disease: New molecular approaches to diagnosis and treatment. Science 1992;256:794–799.
Balicki D, Beutler E: Gaucher disease. Medicine (Baltimore) 1995;74:305–323.
Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL: Phenotypic manifestations of Gaucher disease: Clinical features in 48 biochemically verified type I patients and comment on type II patients; in Desnick RJ, Gatt S, Grabowski GA (eds): Gaucher Disease: A Century of Delineation and Research. New York, Liss, 1982, pp 33–65.
Beutler E: Gaucher disease. Adv Genet 1995;32:17–49.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.